This study was conducted to assess the diagnostic utility of TTF-1, Napsin A, p40, and p63 in accurately subtyping NSCLC on small biopsy specimens, with the objective of identifying a minimal, cost-effective IHC panel suitable for routine clinical practice. This evidence concerns the gene NAPSA and non-small cell lung carcinoma.